Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not yet ...
Barchart on MSN
Nvidia dumped Recursion Pharmaceuticals stock. Should you?
When artificial intelligence (AI) chip maker NVIDIA Corporation (NVDA) heads for the exit, investors instinctively glance at the door. In its latest 13F filing, the chip giant disclosed that it had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results